3 results
To test the hypothesis: the mode of action of benralizumab being ADCC will target both resident and inflammatoryeosinophils whereas mepolizumab only targets inflammatory eosinophils. This will achieved by a head-to-headcomparison of the presence of…
Primary:To evaluate the efficacy of depemokimab 200 mg SC every 26 weeks compared with mepolizumab 300 mg SC every 4 weeks in participants with relapsing or refractory EGPA receiving SoC therapySecondary:- To evaluate the efficacy of depemokimab 200…
We aim to determine the specificity of radiolabelled exendin during the course of T2D and to examine the role of glycemic control on the correlation between pancreatic 111In-exendin uptake, BCM and GLP-1R expression in patients with T2D undergoing (…